Janssen Search
Search results
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
May 31, 2024 Investigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO ...
Dan Pettitt
DAN PETTITT VICE PRESIDENT MARKET ACCESS, IMMUNOLOGY Dan Pettitt is Vice President, Market Access, Immunology for the Global Commercial Strategy Organization, Janssen Global Services. He is responsible for developing product access strategies and ...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and-ineligible patients who are newly diagnosed with multiple myeloma
Jun 03, 2024 88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based induction, ...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
Sep 14, 2024 Spain Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA, September 14, 2024 – Johnson & Johnson ...
Finding Value Through the Product Lifecycle
Article Type: Oncology Establishing and Capturing Value Throughout the Product Lifecycle At Janssen, getting our medicines to patients who will benefit is our mission and why we exist. From a market access perspective, this means that, very early in the ...
Five Things We Know About Pulmonary Arterial Hypertension
Article Block Text: Article Type: Other Awareness & Advocacy Pulmonary Hypertension Five Things We Know About Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a deadly disease, but it can be managed—if you get a timely ...
Five Things We Know About Pulmonary Arterial Hypertension
Five Things We Know About Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a deadly disease, but it can be managed—if you get a timely diagnosis. Here is what the latest science and research has revealed about PAH, including who ...
Igniting Positive Change: A Story for International Women’s Day 2020
Igniting Positive Change: A Story for International Women’s Day 2020 I carpool with a colleague, Brenda. She and I work in different areas of R&D, grew up on different continents and have different tastes in food. But, despite our diverse ...
Neuropsychiatric Disorders: Expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation
Neuropsychiatric Disorders: Expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation Janssen's heritage in neuroscience began more than 60 years ago, when our namesake, Dr. Paul Janssen, developed a drug ...
Partners in Precision Medicine
Our Focus on Collaborations and Partnerships We believe that innovation can come from anywhere and is often the result of unified efforts from multiple collaborators. Janssen has a demonstrated appreciation for the value of collaboration and partnership, ...